FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2077884963> ?p ?o ?g. }

• W2077884963 endingPage "798" @default.
• W2077884963 startingPage "790" @default.
• W2077884963 abstract "Summary. Background: Anticoagulants are expected to promote fibrinolysis by counteracting the antifibrinolytic effects of thrombin, which include thrombin-activatable fibrinolysis inhibitor (TAFI) activation and clot structure enhancement. However, the efficiency of anticoagulants may vary remarkably, and the ability of direct thrombin inhibitors to facilitate clot lysis remains controversial. Objective: To evaluate the profibrinolytic effect of dabigatran, a new, direct thrombin inhibitor, using different in vitro models. Methods and Results: The resistance of tissue factor-induced plasma clots to fibrinolysis by exogenous tissue-type plasminogen activator (t-PA) (turbidimetric method) was reduced by dabigatran in a concentration-dependent manner, with ≥ 50% shortening of lysis time at clinically relevant concentrations (1–2 μm). A similar effect was observed in the presence of low (0.1 and 1 nm) but not high (10 nm) concentrations of thrombomodulin. Acceleration of clot lysis by dabigatran was associated with a reduction in TAFI activation and thrombin generation, and was largely, although not completely, negated by an inhibitor of activated TAFI, potato tuber carboxypeptidase inhibitor. The assessment of the viscoelastic properties of clots showed that those generated in the presence of dabigatran were more permeable, were less rigid, and consisted of thicker fibers. The impact of these physical changes on fibrinolysis was investigated using a model under flow conditions, which demonstrated that dabigatran made the clots markedly more susceptible to flowing t-PA, by a mechanism that was largely TAFI-independent. Conclusions: Dabigatran, at clinically relevant concentrations, enhances the susceptibility of plasma clots to t-PA-induced lysis by reducing TAFI activation and by altering the clot structure. These mechanisms might contribute to the antithrombotic activity of the drug." @default.
• W2077884963 created "2016-06-24" @default.
• W2077884963 creator A5014965874 @default.
• W2077884963 creator A5039033504 @default.
• W2077884963 creator A5054883469 @default.
• W2077884963 creator A5064524635 @default.
• W2077884963 creator A5085969447 @default.
• W2077884963 date "2010-04-01" @default.
• W2077884963 modified "2023-10-14" @default.
• W2077884963 title "Dabigatran enhances clot susceptibility to fibrinolysis by mechanisms dependent on and independent of thrombin‐activatable fibrinolysis inhibitor" @default.
• W2077884963 cites W143004001 @default.
• W2077884963 cites W1503830196 @default.
• W2077884963 cites W1749438314 @default.
• W2077884963 cites W1973274829 @default.
• W2077884963 cites W1988747841 @default.
• W2077884963 cites W2001382396 @default.
• W2077884963 cites W2003711453 @default.
• W2077884963 cites W2005594819 @default.
• W2077884963 cites W2014274164 @default.
• W2077884963 cites W2016541949 @default.
• W2077884963 cites W2022816951 @default.
• W2077884963 cites W2024207765 @default.
• W2077884963 cites W2026599765 @default.
• W2077884963 cites W2035372451 @default.
• W2077884963 cites W2040266997 @default.
• W2077884963 cites W2042215977 @default.
• W2077884963 cites W2042275984 @default.
• W2077884963 cites W2045737844 @default.
• W2077884963 cites W2050013422 @default.
• W2077884963 cites W2056894234 @default.
• W2077884963 cites W2058927570 @default.
• W2077884963 cites W2064232485 @default.
• W2077884963 cites W2068832601 @default.
• W2077884963 cites W2069436323 @default.
• W2077884963 cites W2072719459 @default.
• W2077884963 cites W2078132464 @default.
• W2077884963 cites W2095803174 @default.
• W2077884963 cites W2118399490 @default.
• W2077884963 cites W2120226771 @default.
• W2077884963 cites W2127536162 @default.
• W2077884963 cites W2136489990 @default.
• W2077884963 cites W2152988106 @default.
• W2077884963 cites W2154400398 @default.
• W2077884963 cites W2284685439 @default.
• W2077884963 cites W27238432 @default.
• W2077884963 cites W3189918132 @default.
• W2077884963 cites W55986542 @default.
• W2077884963 cites W71774759 @default.
• W2077884963 doi "https://doi.org/10.1111/j.1538-7836.2010.03739.x" @default.
• W2077884963 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/20088944" @default.
• W2077884963 hasPublicationYear "2010" @default.
• W2077884963 type Work @default.
• W2077884963 sameAs 2077884963 @default.
• W2077884963 citedByCount "90" @default.
• W2077884963 countsByYear W20778849632012 @default.
• W2077884963 countsByYear W20778849632013 @default.
• W2077884963 countsByYear W20778849632014 @default.
• W2077884963 countsByYear W20778849632015 @default.
• W2077884963 countsByYear W20778849632016 @default.
• W2077884963 countsByYear W20778849632017 @default.
• W2077884963 countsByYear W20778849632018 @default.
• W2077884963 countsByYear W20778849632019 @default.
• W2077884963 countsByYear W20778849632020 @default.
• W2077884963 countsByYear W20778849632021 @default.
• W2077884963 countsByYear W20778849632022 @default.
• W2077884963 countsByYear W20778849632023 @default.
• W2077884963 crossrefType "journal-article" @default.
• W2077884963 hasAuthorship W2077884963A5014965874 @default.
• W2077884963 hasAuthorship W2077884963A5039033504 @default.
• W2077884963 hasAuthorship W2077884963A5054883469 @default.
• W2077884963 hasAuthorship W2077884963A5064524635 @default.
• W2077884963 hasAuthorship W2077884963A5085969447 @default.
• W2077884963 hasBestOaLocation W20778849631 @default.
• W2077884963 hasConcept C126322002 @default.
• W2077884963 hasConcept C141071460 @default.
• W2077884963 hasConcept C185592680 @default.
• W2077884963 hasConcept C201267052 @default.
• W2077884963 hasConcept C2776301958 @default.
• W2077884963 hasConcept C2776710957 @default.
• W2077884963 hasConcept C2776825266 @default.
• W2077884963 hasConcept C2777292125 @default.
• W2077884963 hasConcept C2778810321 @default.
• W2077884963 hasConcept C2779161974 @default.
• W2077884963 hasConcept C2779637338 @default.
• W2077884963 hasConcept C2781436528 @default.
• W2077884963 hasConcept C2991743468 @default.
• W2077884963 hasConcept C57002609 @default.
• W2077884963 hasConcept C71924100 @default.
• W2077884963 hasConcept C89560881 @default.
• W2077884963 hasConcept C98274493 @default.
• W2077884963 hasConceptScore W2077884963C126322002 @default.
• W2077884963 hasConceptScore W2077884963C141071460 @default.
• W2077884963 hasConceptScore W2077884963C185592680 @default.
• W2077884963 hasConceptScore W2077884963C201267052 @default.
• W2077884963 hasConceptScore W2077884963C2776301958 @default.
• W2077884963 hasConceptScore W2077884963C2776710957 @default.
• W2077884963 hasConceptScore W2077884963C2776825266 @default.
• W2077884963 hasConceptScore W2077884963C2777292125 @default.

• next